The AASLD has published an update to its practice guidelines for hepatitis C: “An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases.” The guidelines now include recommendations for two drugs, Incivek (telaprevir; Vertex) and Victrelis (boceprevir; Merck), that were approved by the FDA in May 2011. Study data has demonstrated that treatment with Incivek and Victrelis improves cure rates for patients with hepatitis C genotype 1 infection.

Incivek and Victrelis are both indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin in patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based therapy.

The updated guidelines can be accessed at